Results
There were 6,219 leadless and 10,212 transvenous de novo implant
procedures identified during the study period contributing to the
analysis cohort (Table 1 ). Patient baseline characteristics of
this cohort have been previously reported.3 Compared
with transvenous, patients implanted with a leadless VVI pacemaker were
more likely to have ESRD (12.0% vs. 2.3%, P<0.001), renal
dysfunction (48.8% vs. 42.1%, P<0.001), and a higher mean
Charlson Comorbidity Index score (5.1±3.4 vs. 4.6±3.0,
P<0.001). Mean follow-up time for patients implanted with a
leadless VVI pacemaker was 675 days, compared to 727 days for
transvenous (P<0.001). After applying the propensity score
overlap weights, all measured baseline and encounter characteristics
were well balanced with all standardized mean differences near zero.
There were 2,937 patients implanted with a leadless VVI pacemaker and
4,821 patients implanted with a transvenous VVI pacemaker in the
sub-analysis of heart failure hospitalization endpoint analysis cohort
without a prior history of heart failure.